329
Views
0
CrossRef citations to date
0
Altmetric
Case Study

Three Cases of Reported Improvement in Microsmia and Anosmia Following Naturalistic Use of Psilocybin and LSD

ORCID Icon, ORCID Icon, ORCID Icon & ORCID Icon
Pages 672-679 | Received 17 Apr 2023, Accepted 03 Aug 2023, Published online: 31 Aug 2023
 

ABSTRACT

Cultural awareness of anosmia and microsmia has recently increased due to their association with COVID-19, though treatment for these conditions is limited. A growing body of online media claims that individuals have noticed improvement in anosmia and microsmia following classic psychedelic use. We report what we believe to be the first three cases recorded in the academic literature of improvement in olfactory impairment after psychedelic use. In the first case, a man who developed microsmia after a respiratory infection experienced improvement in smell after the use of 6 g of psilocybin containing mushrooms. In the second case, a woman with anosmia since childhood reported olfactory improvement after ingestion of 100 µg of lysergic acid diethylamide (LSD). In the third case, a woman with COVID-19-related anosmia reported olfactory improvement after microdosing 0.1 g of psilocybin mushrooms three times. Following a discussion of these cases, we explore potential mechanisms for psychedelic-facilitated improvement in olfactory impairment, including serotonergic effects, increased neuroplasticity, and anti-inflammatory effects. Given the need for novel treatments for olfactory dysfunction, increasing reports describing improvement in these conditions following psychedelic use and potential biological plausibility, we believe that the possible therapeutic benefits of psychedelics for these conditions deserve further investigation.

Disclosure statement

Dr Barnett has received stock options from CB Therapeutics as compensation for advisory services. He serves as an advisor or consultant for DynaMed Plus (EBSCO Industries, Inc), Cerebral (within the past year, but no longer active) and Janssen Pharmaceuticals. He has received research funding from MindMed. Dr Kovacevich, Dr Weleff, and Dr Claytor report no potential conflicts.

Additional information

Funding

The work was supported by the Consejo Nacional de Ciencia y Tecnología [226454].

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.